ZFGN - Zafgen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.09
+0.38 (+5.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.71
Open6.75
Bid6.67 x 1400
Ask7.74 x 3100
Day's Range6.43 - 7.09
52 Week Range3.21 - 10.00
Volume346,169
Avg. Volume145,228
Market Cap195.424M
Beta-0.75
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today positive full results from the Company’s Phase 2 clinical trial of ZGN-1061, designed to demonstrate proof-of-concept efficacy and safety in patients with type 2 diabetes and establish a minimally effective dose. The trial met all of its primary endpoints at the 0.9 mg dose, and 12-week data demonstrated a favorable safety and tolerability profile, with no treatment-related serious adverse events and no CV safety signals observed. Data for this trial and two supportive nonclinical studies for ZGN-1061 are being presented as late-breaker abstracts at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida.

  • Benzinga7 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements.  ...

  • GlobeNewswire17 days ago

    Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors

    BOSTON, June 07, 2018-- Zafgen, Inc.,, a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic ...

  • GlobeNewswire25 days ago

    Zafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today the appointment of Brian McVeigh as Chief Business Officer. Mr. McVeigh joins Zafgen following a 25-year career with GlaxoSmithKline (GSK) where he held multiple senior-level positions within the global Business Development, Finance, Marketing, Corporate and R&D organizations.

  • Associated Press2 months ago

    Zafgen: 1Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 58 cents. Zafgen shares have climbed 60 percent since the beginning of the year. The stock has risen 54 percent in the last 12 months. ...

  • GlobeNewswire2 months ago

    Zafgen Reports First Quarter 2018 Operating and Financial Results

    Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association Scientific Sessions. ZGN-1061 Phase 1 SAD/ MAD data published in Diabetes, Obesity and Metabolism. BOSTON, ...

  • GlobeNewswire2 months ago

    Zafgen to Present at Deutsche Bank 43rd Annual Health Care Conference

    BOSTON, May 02, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • GlobeNewswire2 months ago

    Zafgen to Host Conference Call to Discuss First Quarter 2018 Financial Results

    BOSTON, May 01, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • Here's Why Zafgen Inc Rose as Much as 21.1% Today
    Motley Fool4 months ago

    Here's Why Zafgen Inc Rose as Much as 21.1% Today

    The biopharma announced full-year 2017 results and several business updates.

  • Associated Press4 months ago

    Zafgen reports 4Q loss

    On a per-share basis, the Boston-based company said it had a loss of 48 cents. For the year, the company reported that its loss narrowed to $52 million, or $1.90 per share. Zafgen shares have climbed 79 ...

  • ACCESSWIRE5 months ago

    Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook

    LONDON, UK / ACCESSWIRE / January 08, 2018 / Active-Investors.com has just released a free research report on Zafgen Inc. (NASDAQ: ZFGN ). If you want access to this report all you need to do is sign up ...

  • Marketwired8 months ago

    Zafgen Reports Third Quarter 2017 Financial Results

    Zafgen, Inc. , a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases, ...

  • When Will Zafgen Inc (ZFGN) Run Out Of Cash?
    Simply Wall St.9 months ago

    When Will Zafgen Inc (ZFGN) Run Out Of Cash?

    As the USD $96.19M market cap Zafgen Inc (NASDAQ:ZFGN) released another year of negative earnings, investors may be on edge waiting for breakeven. Cash is crucial to run a business,Read More...

  • Associated Press10 months ago

    Zafgen reports 2Q loss

    The Boston-based company said it had a loss of 49 cents per share. The company's shares closed at $3.41. A year ago, they were trading at $3.21. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...